REVELATION BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| REVELATION BIOSCIENCES, INC. | ||
| Date: February 26, 2026 | By: | /s/ James Rolke |
|---|---|---|
| James Rolke | ||
| Chief Executive Officer | ||
| (principal executive officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chester S. Zygmont, III and Joseph P. Galda, jointly and severally, their respective attorneys-in-fact, with the power of substitution, for each of them in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or their respective substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Date: February 26, 2026 | By: | /s/ James Rolke |
|---|---|---|
| Chief Executive Officer and Director | ||
| Date: February 26, 2026 | By: | /s/ Chester S. Zygmont, III |
| Chief Financial Officer and Principal Accounting Officer | ||
| Date: February 26, 2026 | By: | /s/ Jennifer Carver |
| Director | ||
| Date: February 26, 2026 | By: | /s/ Jess Roper |
| Director | ||
| Date: February 26, 2026 | By: | /s/ Lakhmir Chawla, MD |
| Director | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID 23) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Changes in Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Consolidated Notes to the Financial Statements | F-8 – F-26 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.